Skip links

We are committed to supporting you to achieve accelerated success in bringing the products and drugs into the market in time-bound manner.

Vipragen Biosciences Pvt. Ltd. is a CRO certified by NGCMA for OECD-GLP to carry out safety studies for regulatory submissions. Additionally, the laboratory has been certified by AAALAC, NABL, and DCGI to support discovery research. Vipragen has deep scientific and research knowledge with a combined experience of over 150 years of the senior leadership team in areas such as General Toxicology, Reproductive Toxicology, Genetic Toxicology, Pharmacology, Analytical Chemistry, Bioanalytical and ADME.

Located in the heritage city of Mysore, Vipragen has been serving companies worldwide for over a decade. We serve clients with diverse research requirements and assist to advance their product portfolio with reliable data, compliant with global quality standards. The robust platform development programs at Vipragen with global partners enable collaborations to bring innovative solutions to create a safer tomorrow.

Our Mission

We at Vipragen, are focused on offering high-quality science and reliable data delivery across the industrial spectrum for a safer tomorrow. We value life and our every action is driven by a greater sense of ethical and social responsibility to enrich scientific advancement impacting the community at large.

Our Values

Quality

Vipragen offers quality services adhering to international standards. As quality is deeply ingrained in the DNA of Vipragen, we emphasize Good Laboratory Practices and carry out regulatory studies following international guidelines.

Capability

Team of scientists with a combined experience of 150+ years with expertise in various areas like Molecular biology, in vitro biology, Toxicology, Pharmacology, Microbiology, Analytical Bioanalytical and Veterinary sciences.

End-to-End Solution

The drug discovery is a highly complex journey and safety and Efficacy are its key cornerstones. A success of a therapeutic is about delivering the safe and effective treatment to patients. Pre-clinical testing plays a vital role in this process.

Leadership

Chandrashekaran Siddamadappa

Dr. S Chandrashekaran

Chairman & Managing Director
Chaitra Harsha

Dr. Chaitra Harsha

Joint Managing Director
Dr VV Vaidyanathan

Dr. V. V. Vaidyanathan

Director - Assets & Discovery Collaborations

Dr. Pradeep Takawale

Head - Preclinical Services and TFM

Dr. Nagendra S L

Head - Quality Assurance Unit
Saravanan Muthaiah

Saravanan Muthaiah

Head - Dept. of Toxicology

Accolades

Vipragen is the Winner of Elevate 100

Elevate

As a part of ELEVATE Program in 2017 and identified as one of the most innovative firms in the state, an initiative of the Department of Information Technology and Biotechnology, the Government of Karnataka aims to provide a comprehensive entrepreneurship platform for startups. The event was envisioned to provide startups with the necessary boost at various stages through funding or mentoring as key enablers. As a result of this Vipragen has completed the project aimed at using in vitro scaffold 3D culture cell models that can be used as alternatives for animal testing.

More info here: https://startup.karnataka.gov.in/elevate-100/#winnerList

Collaborations

Vipragen aims to partner with any Bio-innovators to co-develop molecules through unique technology platforms. Our collaborators can benefit from the advanced Artificial intelligence co-developers for smarter and faster drug discovery programs. Vipragen is also focused on Nextgen alternate to animal testing as a part of the cell-based safety pharmacology assays, that are being validated at a fast pace. Vipragen welcomes start-ups and sponsor collaborators to make the most of such platforms and constantly add value to research by effective delivery.

Vipragen Collaborates with JSS Medical College

Vipragen collaborates with JSS group of Hospitals

Vipragen signs an MOU with the JSS group of Hospital Mysore which is a part of JSS Medical College for a strategic collaboration for looking at holistic approach to healthcare. Through the collaboration the two groups are poised to take on pressing challenge pertaining to gap between Preclinical Drug testing to clinical In-patient approach. In the vision to perform an end to end Drug Development possibility and provide the collaborative partner with a comprehensive solution from Lab to Market. It is an absolute honour to integrate with the prestigious premiere institute such as JSS to make the clinical testing more versatile, with integrated project and data management. With this collaboration, Vipragen is poised to address the growing need to make drug discovery and development affordable.

JNC Collaboration

Vipragen JNC Collaboration

Vipragen Biosciences has partnered with the Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) in Bengaluru to help to identify the drug candidates that could potentially cure neurodegenerative diseases (ND) such as Alzheimer’s and Parkinson’s. The research theorizes that the main cause of neurodegenerative diseases is an accumulation of toxic protein clumps inside neurons in aged individuals. However, these aggregates could be cleared using small molecules that accelerate an intracellular recycling mechanism called autophagy.

“We can use the proprietary platform to identify the new drug candidates for neurodegeneration” says Dr Chaitra Harsha, Joint MD, Vipragen Biosciences. The firm will carry forward testing of potential drug candidates which showed promise in preclinical animal trials as part of a public-private partnership.

Vipragen and Transcell Collaboration

Vipragen in partnership with Transcell to offer an alternative Non-Human testing platforms for wide range of application. This collaboration allows the industry partners in the Pharma, Biopharma, Agrochemical and herbal space to enable a new platform discovery offerings which is integrated as a part of exploratory regime. Vipragen believes firmly in the 3Rs Approach – Reduction, Replacement and Refinement as a significant step to animal welfare principals, Transcell partnership will enable an alternative testing platforms which results in lower testing costs and time.

Vipragen now addresses the growing need for innovative alternative to Invivo Toxicity testing, as this partnership facilitates in human sourced primary, progenitor cell based platforms, the read outs would be a 100% physiologically relevant to human/patient conditions supporting industries across spectrum.

Know more in under Discovery Services.

Vipragen has performed Integrated Drug Discovery projects funded by BIRAC in collaboration with other partner organizations supported by BIRAC (DST, India government schemes) in exploring drug candidates to be implicated as therapeutics against oncology and autoimmune disorders. Vipragen has presented collaborative work in global symposiums.

Chandrashekaran Siddamadappa

Dr. S Chandrashekaran

Chairman & Managing Director

Dr. Chandra is the Founding Chairman and Managing Director of Vipragen Biosciences Pvt Ltd., a Pre-clinical drug discovery company situated in Mysore. Chandra has a formidable years of hands-on-experience in successfully running and managing Biotech start-up companies.

He has more than 30 years of experience in the areas of recombinant technologies, Biochemistry, in vitro Biology, Drug Discovery and Biopharma. He founded Enzene Biosciences Ltd., a Biopharma R&D company and was instrumental in setting up Biologics (including Peptides, rDNA drugs and monoclonal antibody) platform and took a couple of Biosimilars to clinical studies, and several to Pre-clinical stage successfully. An aggressive value creator and 30X serial entrepreneur who is currently front-ending Vipragen.

Chaitra Harsha

Dr. Chaitra Harsha

Joint Managing Director

Dr Chaitra is a Medical Graduate (MBBS) and PhD from Indian Institute of science, Bengaluru. She holds MPWE (Management Program for Women Entrepreneurs) from NSRCL for Entrepreneurship, IIM, Bengaluru. She is a serial entrepreneur, with two successfully executed ventures in healthcare and education. Her contribution in the healthcare space is vast and currently she is a Joint Managing Director of Vipragen team.

With excellent academic credentials and a proficient management skill set through centers of excellence of global reputation, Dr Chaitra Harsha has emerged as a thought leader in the areas of Healthcare and Biotechnology.

Dr VV Vaidyanathan

Dr. V. V. Vaidyanathan, M. Sc., Ph. D

Project Director & Site-Head

An alumnus of IISc, Bangalore, Dr. Vaidyanathan has over 28 years of experience in academic research (MHH Hannover, Germany; NCI, Bethesda, USA), pharma industry (Astra India) & CRO (Aurigene & Syngene International). He has participated in many small molecule discovery programs such as Infectious Diseases (TB), Apoptosis (Caspase-3), Oncology (PARP inhibitors, ADC), Inflammation (Sepsis) and Metabolic disorders (Diabetes/Obesity) thus gaining in-depth experience in key aspects of discovery research such as screening, DMPK and Pharmacology models. His vast experience in biological research enables Vipragen to provide customized solutions to clients to accelerate discovery programs.

He is a recipient of the prestigious Alexander Humboldt Fellowship and is a Fogerty International Fellow at NIH, Bethesda, USA.

Dr Pradeep Takawale, MVSc

Head – Preclinical Services and TFM

Dr. Pradeep Takawale, a veterinarian by education, holds a master’s degree in veterinary pharmacology and toxicology from Chandra Shekhar Azad university Kanpur, India. He has more than 20 years of experience in the field of general toxicology, reproductive and developmental toxicology (DART), juvenile toxicology and pharmacokinetics. He has authored 175+ regulatory toxicity study reports of various study types as per the relevant international guidelines for regulatory submissions.

In the last 20 years, he has served various organizations like JRF global India, CiToxLAB Scantox Denmark, Zydus Cadila India, Ranbaxy India and Eurofins BSL Bio service Munich Germany and contributed to the progress of these organizations.

Dr. Nagendra S L, BVSc., Ad. PGDB

Head – Quality Assurance Unit

Dr. Nagendra S L is a Veterinarian , Additionally holds a Post graduate Diploma in Bioinformatics. He has served the pre-clinical industry over a period of 30+ years in the field of quality assurance having vast experience of reviewing GLP documents (study plans, study reports, SOPs – 2500+ to 3000 in each category), and (overall 4000+ inspections) and archival procedures as per GLP. Additionally, he has vast experience in designing and implementing the SOPs as per GLP and AAALAC requirements.

He has excellent knowledge about other quality management systems like ISO, NABL, GMP, GCP, GDP, R&D of pharmaceutical industry, having served in organizations like Rallis India Ltd, Jubilant Biosys Pvt. Ltd., Vimta Labs Pvt. Ltd., Bioneeds.

Saravanan Muthaiah

Saravanan Muthaiah

Head – Dept. of Toxicology

Saravanan is Post Graduate (M.Sc Biochemistry) from Bharathidasan University, PG Diploma in Bioinformatics and possessing 21 years total experience in academic as well regulatory toxicology. He has vast experience in designing toxicology studies for GRAS, REACh, EFSA, IND, ECHA, NDA, ANDA, RCGM, DCGI submission. He also has vast experience of handling AAALAC, NGCMA, DTL, NABL and Sponsor audits. Presently he is the Deputy Test Facility Management possessing Techno-commercial outlook as technical engagements with International clients and the relevant regulatory requirements. With serving over many years in Vipragen Saravanan has been key in establishing the in-silico platform at Vipragen.

This website uses cookies to improve your web experience.